Filing Flows › Aclaris Therapeutics (ACRS) › Guidance & outlook
Aclaris Therapeutics (ACRS) guidance and outlook
Aclaris Therapeutics' 10-Q filed Nov 5, 2026 makes 28 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency.
- We expect to announce top-line data in the fourth quarter of 2026.
- We intend to initiate a Phase 2b trial in eosinophilic esophagitis in early 2027.
- We plan to conduct a phased Phase 2b basket study of modzatinib in the three most common subtypes of lichen planus: oral erosive lichen planus, cutaneous lichen planus and lichen planopilaris.
- We expect to initiate the Phase 2b trial with the oral erosive lichen planus cohort in the fourth quarter of 2026.
- We expect to file an Investigational New Drug (“IND”) application for ATI-9494 in the fourth quarter of 2026.
- Our approach involves the following mechanisms: (1) reversible and irreversible covalent inhibitors, (2) molecular glue/complex targeted inhibitors, (3) tissue specific inhibitors, and (4) targeted protein degraders.
- Our small molecule discovery efforts center on targeting kinases that play pivotal roles in various inflammatory and autoimmune pathways.
- Our discovery efforts to develop multi-specific antibodies are focused on generating antibodies with superior target affinity, specificity, and potency utilizing combinations of (a) two or more clinically validated targets with non-overlapping biology, (b) clinically validated targets with novel biology, and/or (c) synergistic target combinations in an effort to address shortcomings of single drug administration.
- This complementary approach to our small molecule programs enables us to pursue optimal therapeutic modalities for each target and indication of interest.
- For example, we are progressing multi-specific antibodies utilizing the bosakitug anti-TSLP binding region paired with binding fragments targeting other undisclosed cytokine signaling pathways.
- We intend to evaluate both internal and external development options, including strategic partnerships, for these assets.
Aclaris Therapeutics' latest quarter
Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year), net loss $18.5M, operating cash flow −$24.1M. The chart follows the revenue to costs, profit and cash.
Questions
What does Aclaris Therapeutics expect?
Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency. We expect to announce top-line data in the fourth quarter of 2026. We intend to initiate a Phase 2b trial in eosinophilic esophagitis in early 2027.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.